HPLC-MS analysis for determination of plasma concentrations
The supernatant were analyzed using a liquid phase system, which
included the Waters ACQUITY Ultra Performance Liquid Chromatography
I-Class Plus system, equipped for the analysis of Bosutinib, Nintedanib,
Rivaroxaban, Apixaban, and Vilazodone, as well as a High Performance
Liquid Chromatography system (Shimadzu LC), used for the analysis of
Fostamatinib, Ponatinib, Axitinib, Crizotinib, Venetoclax, Ibrutinib,
Sonidegib, Roflumilast, Suvorexant, Apremilast, Elagolix,
Istradefylline, Panobinostat, Rolapitant, Tasimelteon, Fedratinib,
Lenvatinib, Pomalidomide, Ruxolitinib, Ospemifene, Edoxaban,
Baricitinib, Vorapaxar, Flibanserin, Macitentan, Safinamide, and
Tofacitinib. Separation of the analytes was achieved using a
reversed-phase ACE T3 column (1.8 μm, 2.1×50 mm) and the mobile phase
consisted of 0.1% formic acid in water for the A phase and 0.1% formic
acid in acetonitrile for the B phase. The samples concentrations were
then determined using a Triple Quad 6500+ mass spectrometer (Applied
Biosystems, USA), equipped with electron spray ionization (ESI) and a
tandem quadruple mass analyzer. Data processing was performed using
Analyst software (SCIEX), and the mass spectrum parameters can be found
in Table S1.